Form D · Biotechnology
Deciphera Pharmaceuticals, LLC
Waltham, MA · CIK 0001654151
Offering snapshot reported Jun 5, 2017 · SEC filing
- Reported sold
- $52.3M Offering amount: $52.3M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 26, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 5, 2017 | Initial | $52,299,628 | No comparison | 7 | SEC filing |
| Jul 14, 2016 | Amendment | $90,604,034 | $69,052,452vs Sep 29, 2015 | 5 | SEC filing |
| Sep 29, 2015 | Initial | $21,551,582 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-288027
Source: Form D, filed Jun 5, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Patricia L. Allen | Director |
| Edward J. Benz, Jr. | Director |
| James A. Bristol, Ph.D. | Director |
| Daniel L. Flynn, Ph.D. | Executive |
| Thomas Kelly | Executive |
| John Martin | Director |
| Christopher J. Morl | Executive |
| Liam Ratcliffe, M.D., Ph.D. | Director |
| Oliver Rosen, M.D. | Executive |
| Michael Ross | Director |
| Michael Taylor | Director, Executive |
| Michael D. Taylor, Ph.D. | Director, Executive |
| Dennis Walsh | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
500 Totten Pond Road 6th Floor
Waltham, MA, 02451
Waltham, MA, 02451